Sep 25, 2025 7:15am EDT Capricor Therapeutics Provides Regulatory Update on Deramiocel Program for Duchenne Muscular Dystrophy Following Type A Meeting
Sep 9, 2025 9:20am EDT Capricor Therapeutics Responds to FDA Posting of Complete Response Letter (CRL) for Deramiocel
Aug 11, 2025 4:30 pm EDT Capricor Therapeutics Second Quarter 2025 Financial Results and Corporate Update Conference Call